TARA Protara Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 11, 2026
$2.70
· of 52w range
· above low
· to high
$2.6252w low
$7.8252w high
Market Cap (MRQ)
$160M
P/E
-2.0
EPS
$-1.34
your badges
52W Range
$3–$8
Analyst Rating
BUY
Price Target
$26
P/E
-2.0
ROE
-33.7%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
TARA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$2.70
Market Cap (MRQ)
$160M
P/E
-2.0
EPS
$-1.34
ROE
-33.7%
52W Range
$3–$8
TARA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Jan. 10, 2020 | 1-for-40 | Reverse |
About Protara Therapeutics, Inc. - Common Stock Company overview from Wikipedia
Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts and Kansas City, Missouri.
Company History
Proteon was founded by Dr. F. Nicholas Franano based on technology created at Johns Hopkins University. Major investors in the company include MPM Capital, Rockhill Partners, TVM Capital, Skyline Ventures, Prism VentureWorks, Vectis Life Sciences and Intersouth Partners. They have invested over $72 million in the company.
The company is led by Timothy Noyes, CEO; Steven Burke, CMO; George Eldridge, CFO; and Scott Toner, director of marketing.
On March 5, 2009, the company announced that it had raised $32 million from its existing investors plus MPM Capital and Vectis Life Sciences. Proteon also announced that it had entered into an option agreement to be acquired by Novartis for up to $550 million. The company went public in 2014.
In September 2019, Proteon Therapeutics merged with ArTara Therapeutics.
PRT-201
Proteon is developing PRT-201 (vonapanitase), a drug to improve blood flow following vascular surgery procedures, and, more broadly, is interested in vascular access for hemodialysis and peripheral arterial disease (PAD). PRT-201 is a recombinant human elastase manufactured for Proteon by Lonza.
In September 2008, the company announced that the Food and Drug Administration had granted fast track status to PRT-201.
In December 2016, they announced that the phase III trial of PRT-201 hadn't reached its primary endpoint, causing Proteon's stock price to drop more than 75%.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryBiotechnology
employees46
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
EPS$-1.342021-12-31 → 2025-12-31
Free Cash Flow$-56M2016-12-31 → 2025-12-31
Net margin·2020-12-31 → 2020-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | TARA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -2.05Y avg ≈-1.8 | ≈-1.8 | · | · | |
| P/B (MRQ) | 1.05Y avg ≈0.7 | ≈0.7 | 2.1 | Undervalued | |
| Price / FCF | -2.65Y avg ≈-2.8 | ≈-2.8 | · | · | |
| Price / Cash Flow | -2.65Y avg ≈-2.8 | ≈-2.8 | · | · | |
| Price / Tangible Book | 0.75Y avg ≈0.7 | ≈0.7 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | TARA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -29.4%5Y avg ≈-35.4% | ≈-35.4% | -34.2% | In line | |
| ROE | -33.7%5Y avg ≈-41.7% | ≈-41.7% | -46.8% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | TARA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 11.05Y avg ≈15.6 | ≈15.6 | 8.0 | Strong liquidity | |
| Quick Ratio | 14.25Y avg ≈15.3 | ≈15.3 | 7.8 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
12.0%
Next Report
Nov 09, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 10, 2026 | $-0.36 | $-0.33 | -8.4% |
| March 31, 2026 | $-0.31 | $-0.38 | 18.8% | |
| Dec. 31, 2025 | $-0.37 | $-0.33 | -11.6% | |
| Sept. 30, 2025 | $-0.31 | $-0.39 | 20.9% | |
| June 30, 2025 | $-0.35 | $-0.41 | 15.3% | |
| March 31, 2025 | $-0.29 | $-0.46 | 37.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| R&D Expense | $43M | $32M | $25M | $17M | $21M | $12M | $4M | $12M | $22M | $19M | $12M | $6M | |
| SG&A Expense | $22M | $17M | $19M | $21M | $26M | $22M | $4M | $10M | $9M | $10M | $8M | $4M | |
| Operating Expenses | $65M | $49M | $44M | $67M | $47M | $34M | $8M | $21M | $30M | $29M | $21M | $11M | |
| Operating Income | $-65M | $-49M | $-44M | $-67M | $-47M | $-34M | $-8M | $-21M | $-30M | $-29M | $-21M | $-8M | |
| Interest Expense | · | · | · | · | $0 | $34.0K | · | · | · | · | · | $857.0K | |
| Interest Income | $6M | $4M | $3M | $1M | $237.0K | $500.0K | · | · | · | · | · | · | |
| Other Non-op | $7M | $5M | $3M | $1M | $237.0K | $466.0K | · | $207.0K | $139.0K | $-14.0K | $-651.0K | $5M | |
| Pretax Income | $57M | $45M | · | · | · | · | $-15M | $-21M | $-30M | $-29M | $-21M | $-3M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | $-110.0K | |
| Net Income | $-57M | $-45M | $-40M | $-66M | $-47M | $-34M | $-8M | $-21M | $-30M | $-29M | $-21M | $-3M | |
| EPS (Basic) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 | · | · | · | · | · | · | · | |
| Shares (Basic) | 42,836,129 | 20,592,847 | 11,331,338 | 11,259,615 | · | · | · | · | · | · | · | · | |
| Shares (Diluted) | 42,836,129 | 20,592,847 | 11,331,338 | 11,259,615 | 11,232,576 | · | · | · | · | · | · | · | |
| EBITDA | $-65M | $-49M | $-44M | $-67M | $-47M | $-34M | $-15M | · | · | $-29M | $-21M | $-8M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $50M | $163M | $40M | $24M | $36M | $169M | $564.0K | $19M | $21M | $36M | $40M | $69M | |
| Short-term Investments | $106M | $7M | $26M | $60M | $56M | · | · | $2M | $21M | $5M | $25M | $15M | |
| Prepaid Expense | $4M | $2M | $3M | $2M | $2M | $787.0K | $78.0K | $1M | $1M | $1M | $1M | $1M | |
| Other Current Assets | $65.0K | $2.0K | $37.0K | $127.0K | $34.0K | $52.0K | · | · | · | · | · | · | |
| Current Assets | $160M | $172M | $69M | $86M | $93M | $169M | $764.0K | $23M | $43M | $43M | $67M | $85M | |
| PP&E (Net) | $759.0K | $1M | $1M | $2M | $2M | $1M | $459.0K | $263.0K | $259.0K | $372.0K | $224.0K | $83.0K | |
| PP&E (Gross) | $2M | $2M | $2M | $2M | $2M | $1M | $475.0K | $1M | $971.0K | $937.0K | $665.0K | $467.0K | |
| Accum. Depreciation | $1M | $1M | $824.0K | $483.0K | $236.0K | $119.0K | $16.0K | $827.0K | $712.0K | $565.0K | $441.0K | $384.0K | |
| Goodwill | · | · | · | · | $30M | $30M | · | · | · | · | · | · | |
| Other Non-current Assets | $20.0K | $27.0K | $11.0K | $16.0K | $865.0K | $1M | · | · | $218.0K | $393.0K | $706.0K | $114.0K | |
| Total Assets | $209M | $181M | $79M | $113M | $173M | $203M | $1M | $24M | $44M | $44M | $68M | $85M | |
| Accounts Payable | $3M | $4M | $2M | $2M | $954.0K | $914.0K | $716.0K | $441.0K | $291.0K | $556.0K | $1M | $917.0K | |
| Accrued Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $3M | $3M | $9M | $5M | $3M | $1M | |
| Current Liabilities | $11M | $11M | $6M | $6M | $4M | $3M | $3M | $3M | $9M | $5M | $4M | $2M | |
| Capital Leases | $2M | $3M | $4M | $5M | $6M | $999.0K | · | · | · | · | · | · | |
| Total Liabilities | $13M | $14M | $11M | $11M | $11M | $4M | $3M | $3M | $9M | $5M | $4M | $2M | |
| Common Stock | $54.0K | $35.0K | $11.0K | $11.0K | $11.0K | $11.0K | $3.0K | · | $18.0K | $17.0K | $16.0K | $16.0K | |
| Paid-in Capital | $499M | $412M | $269M | $263M | $256M | $246M | $11M | $209M | $203M | $198M | $195M | $192M | |
| Retained Earnings | $-302M | $-245M | $-200M | $-160M | $-94M | $-47M | $-13M | $-210M | $-190M | $-160M | $-131M | $-110M | |
| AOCI | $90.0K | $2.0K | $-31.0K | $-688.0K | $-211.0K | · | $3.0K | $5.0K | $-14.0K | · | $-11.0K | $-6.0K | |
| Stockholders' Equity | $196M | $167M | $68M | $102M | $162M | $199M | $-2M | $5M | $35M | $38M | $63M | $82M | |
| Liabilities + Equity | $209M | $181M | $79M | $113M | $173M | $203M | $1M | $24M | $44M | $44M | $68M | $85M | |
| Shares Outstanding | 53,587,260 | 35,044,772 | 11,364,903 | 11,267,389 | 11,235,731 | 11,211,840 | 2,627,533 | 481,091 | 17,674,729 | 16,603,559 | 16,501,500 | 16,448,455 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $123.0K | $57.0K | $30.0K | |
| Stock-based Comp | $4M | $4M | $6M | $7M | $10M | $10M | $424.0K | $3M | $3M | $3M | $2M | $459.0K | |
| Deferred Tax | $-11M | $-20M | $-14M | $-9M | $-5M | $-9M | · | · | · | · | · | · | |
| Restructuring | · | · | · | · | · | · | $3M | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $1M | $2M | $-7M | |
| Operating Cash Flow | $-56M | $-36M | $-38M | $-26M | $-35M | $-23M | $-5M | $-23M | $-22M | $-24M | $-18M | $-10M | |
| CapEx | $94.0K | $63.0K | $45.0K | $120.0K | $596.0K | $884.0K | $475.0K | $119.0K | $35.0K | $271.0K | $198.0K | $51.0K | |
| Investing Cash Flow | $-139M | $19M | $53M | $15M | $-98M | $3M | $-475.0K | $18M | $-16M | $20M | $-11M | · | |
| Stock Issued | · | · | · | · | · | $74M | · | · | · | · | · | $62M | |
| Stock Repurchased | · | · | $91.0K | $90.0K | $228.0K | · | · | · | · | · | · | · | |
| Net Stock Activity | · | · | $-91.0K | $-90.0K | $-228.0K | $66M | · | · | · | · | · | $62M | |
| Financing Cash Flow | $83M | $140M | $-91.0K | $-90.0K | $-228.0K | $189M | $500.0K | $3M | $23M | $208.0K | $163.0K | · | |
| Net Change in Cash | · | · | · | · | · | · | $-13M | $-2M | $-15M | $-4M | $-29M | $66M | |
| Free Cash Flow | $-56M | $-36M | $-38M | $-27M | $-35M | $-24M | $-16M | · | · | $-24M | $-18M | $-10M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | -7391.4% | · | · | · | · | · | -257.1% | |
| Net Margin | · | · | · | · | · | -7291.4% | · | · | · | · | · | -113.4% | |
| EBITDA Margin | · | · | · | · | · | -7391.4% | · | · | · | · | · | -256.1% | |
| ROA | -29.4% | -34.2% | -42.0% | -46.1% | -25.1% | -33.2% | -98.3% | · | · | -51.4% | -28.1% | -7.4% | |
| ROE | -33.7% | -35.8% | -55.6% | -54.7% | -28.4% | -17.2% | -449.1% | · | · | -56.0% | -29.3% | 37.0% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.6 | 15.7 | 11.2 | 15.0 | 21.7 | 58.1 | 12.0 | · | · | 8.4 | 16.1 | 36.2 | |
| Quick Ratio | 14.2 | 15.5 | 10.7 | 14.7 | 21.2 | 57.8 | 10.6 | · | · | 8.1 | 15.8 | 35.8 | |
| Interest Coverage | · | · | · | · | · | -1013.1 | · | · | · | · | · | -8.8 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | 0.0 | · | · | · | · | · | 0.1 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.67 | $4.77 | $6.01 | $9.06 | $14.41 | $17.77 | $11.46 | · | · | $2.32 | $3.84 | $5.01 | |
| Cash Flow / Share | $-1.32 | $-1.74 | $-3.31 | $-2.35 | · | · | · | · | · | · | · | · | |
| Cash / Share | $0.93 | $4.65 | $3.48 | $2.14 | $3.18 | $15.04 | $11.08 | · | · | $2.19 | $2.43 | $4.19 | |
| EPS (TTM) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| Net Income TTM | $-57M | $-45M | $-40M | $-66M | $-47M | $-34M | $-8M | $-21M | $-30M | $-29M | $-21M | $-3M | |
| Market Cap | $286M | $185M | $21M | $30M | $76M | $271M | $9M | · | · | $1.26B | $10.24B | $6.84B | |
| P/E | -4.0 | -2.4 | -0.5 | -0.5 | -1.6 | · | · | · | · | · | · | · | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | 2321.1 | |
| P/B | 1.5 | 1.1 | 0.3 | 0.3 | 0.5 | 1.4 | 1.4 | · | · | 32.8 | 161.5 | 83.0 | |
| P / Tangible Book | 1.5 | 1.1 | 0.3 | 0.3 | 0.6 | 1.6 | · | · | · | · | · | · | |
| P / Cash Flow | -5.1 | -5.2 | -0.6 | -1.1 | -2.2 | -11.6 | -0.6 | · | · | -53.3 | -582.8 | -684.9 | |
| P / FCF | -5.1 | -5.2 | -0.6 | -1.1 | -2.2 | -11.2 | -0.6 | · | · | -52.7 | -576.3 | -681.5 | |
| Earnings Yield | -25.1% | -41.1% | -190.4% | -218.7% | -62.4% | · | · | · | · | · | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $17M | $14M | $13M | $10M | $11M | $9M | $9M | $8M | $6M | $8M | $6M | $6M | $7M | $5M | $5M | $3M | |
| SG&A Expense | $6M | $6M | $6M | $5M | $6M | $5M | $5M | $4M | $4M | $4M | $5M | $4M | $5M | $5M | $5M | $5M | |
| Operating Expenses | $23M | $20M | $19M | $15M | $17M | $14M | $14M | $12M | $11M | $12M | $11M | $11M | $12M | $10M | $40M | $8M | |
| Operating Income | $-23M | $-20M | $-19M | $-15M | $-17M | $-14M | $-14M | $-12M | $-11M | $-12M | $-11M | $-11M | $-12M | $-10M | $-40M | $-8M | |
| Interest Income | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $756.0K | $820.0K | $840.0K | $846.0K | $687.0K | $542.0K | $283.0K | |
| Other Non-op | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $756.0K | $820.0K | $840.0K | $846.0K | $687.0K | $542.0K | $283.0K | |
| Net Income | $-22M | $-18M | $-17M | $-13M | $-15M | $-12M | $-13M | $-11M | $-10M | $-11M | $-10M | $-10M | $-11M | $-9M | $-39M | $-8M | |
| EPS (Basic) | $-0.36 | $-0.31 | $-0.39 | $-0.31 | $-0.35 | $-0.29 | $-0.25 | $-0.50 | $-0.45 | $-0.97 | $-0.90 | $-0.87 | $-1.00 | $-0.80 | $-3.46 | $-0.68 | |
| EPS (Diluted) | $-0.36 | $-0.31 | $-0.39 | $-0.31 | $-0.35 | $-0.29 | $-0.25 | $-0.50 | $-0.45 | $-0.97 | $-0.90 | $-0.87 | $-1.00 | $-0.80 | $-3.46 | $-0.68 | |
| Shares (Basic) | 61,006,766 | 57,538,833 | · | 42,272,104 | 42,270,855 | 40,707,937 | · | 22,329,772 | 21,233,163 | 11,420,948 | · | 11,347,887 | 11,307,842 | 11,303,869 | · | 11,265,475 | |
| Shares (Diluted) | 61,006,766 | 57,538,833 | · | 42,272,104 | 42,270,855 | 40,707,937 | · | 22,329,772 | 21,233,163 | 11,420,948 | · | 11,347,887 | 11,307,842 | 11,303,869 | · | 11,265,475 | |
| EBITDA | $-23M | $-20M | · | $-15M | $-17M | $-14M | · | $-12M | $-11M | $-12M | · | $-11M | $-12M | $-10M | · | $-8M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17M | $15M | $50M | $13M | $31M | $91M | $163M | $52M | $90M | $52M | $40M | $34M | $34M | $21M | $24M | $47M | |
| Short-term Investments | $125M | $121M | $106M | $120M | $91M | $33M | $7M | $30M | · | $3M | $26M | $40M | $46M | $66M | $60M | $49M | |
| Prepaid Expense | $4M | $4M | $4M | $3M | $3M | $2M | $2M | $4M | $3M | $3M | $3M | $4M | $4M | $8M | $2M | $2M | |
| Other Current Assets | $230.0K | $17.0K | $65.0K | $218.0K | $78.0K | $16.0K | $2.0K | $3.0K | $4.0K | $3.0K | $37.0K | $2.0K | $1.0K | $127.0K | $127.0K | · | |
| Current Assets | $146M | $140M | $160M | $136M | $125M | $127M | $172M | $85M | $92M | $58M | $69M | $78M | $84M | $95M | $86M | $99M | |
| PP&E (Net) | $1M | $669.0K | $759.0K | $828.0K | $912.0K | $988.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | |
| PP&E (Gross) | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | |
| Accum. Depreciation | · | · | $1M | · | · | · | $1M | · | · | · | $824.0K | · | · | · | $483.0K | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $30M | |
| Other Non-current Assets | $74.0K | $76.0K | $20.0K | $21.0K | $29.0K | $35.0K | $27.0K | $33.0K | $19.0K | $31.0K | $11.0K | $3M | $3M | $586.0K | $16.0K | $734.0K | |
| Total Assets | $176M | $192M | $209M | $145M | $157M | $169M | $181M | $94M | $102M | $68M | $79M | $88M | $95M | $106M | $113M | $149M | |
| Accounts Payable | $5M | $4M | $3M | $5M | $5M | $2M | $4M | $2M | $1M | $972.0K | $2M | $3M | $2M | $4M | $2M | $456.0K | |
| Accrued Liabilities | $7M | $4M | $6M | $4M | $3M | $4M | $5M | $5M | $3M | $4M | $3M | $3M | $2M | $1M | $3M | $2M | |
| Current Liabilities | $13M | $9M | $11M | $10M | $10M | $7M | $11M | $9M | $6M | $6M | $6M | $7M | $5M | $6M | $6M | $4M | |
| Capital Leases | $1M | $2M | $2M | $2M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $6M | |
| Total Liabilities | $15M | $11M | $13M | $12M | $13M | $10M | $14M | $12M | $10M | $10M | $11M | $12M | $10M | $12M | $11M | $9M | |
| Common Stock | $59.0K | $55.0K | $54.0K | $39.0K | $39.0K | $39.0K | $35.0K | $21.0K | $21.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | |
| Paid-in Capital | $503M | $502M | $499M | $417M | $416M | $415M | $412M | $314M | $313M | $270M | $269M | $267M | $266M | $264M | $263M | $261M | |
| Retained Earnings | $-342M | $-320M | $-302M | $-285M | $-272M | $-257M | $-245M | $-232M | $-221M | $-211M | $-200M | $-190M | $-180M | $-169M | $-160M | $-121M | |
| AOCI | $-363.0K | $-364.0K | $90.0K | $143.0K | $77.0K | $89.0K | $2.0K | $29.0K | · | $-1.0K | $-31.0K | $-165.0K | $-336.0K | $-469.0K | $-688.0K | $-1M | |
| Stockholders' Equity | $161M | $181M | $196M | $132M | $144M | $158M | $167M | $82M | $92M | $58M | $68M | $77M | $85M | $95M | $102M | $139M | |
| Liabilities + Equity | $176M | $192M | $209M | $145M | $157M | $169M | $181M | $94M | $102M | $68M | $79M | $88M | $95M | $106M | $113M | $149M | |
| Shares Outstanding | 59,083,935 | 55,055,582 | 53,587,260 | 38,587,260 | 38,581,863 | 38,577,813 | 35,044,772 | 20,629,772 | 11,364,903 | 11,433,837 | 11,364,903 | 11,364,903 | 11,307,962 | 11,306,753 | 11,267,389 | 11,267,389 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $1M | $1M | $1M | $903.0K | $833.0K | $904.0K | $931.0K | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $1M | |
| Operating Cash Flow | $-15M | $-21M | $-17M | $-12M | $-12M | $-15M | $-9M | $-8M | $-8M | $-10M | $-9M | $-7M | $-9M | $-13M | $-5M | $-5M | |
| CapEx | · | · | $24.0K | $4.0K | $22.0K | $44.0K | $0 | $8.0K | · | · | $0 | $37.0K | $2.0K | $6.0K | $6.0K | $83.0K | |
| Investing Cash Flow | $18M | $-15M | $-27M | $-7M | $-48M | $-58M | $22M | $-29M | $3M | $23M | $15M | $6M | $22M | $10M | $-18M | $19M | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | $76.0K | · | $27.0K | $0 | $64.0K | $0 | $18.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $-76.0K | · | · | · | $-64.0K | · | · | |
| Financing Cash Flow | $-26.0K | $1M | $81M | $13.0K | $8.0K | $2M | $98M | $0 | $42M | $-76.0K | $0 | $-27.0K | $0 | $-64.0K | $0 | $-18.0K | |
| Free Cash Flow | · | · | · | · | · | $-15M | · | · | · | · | · | · | · | $-13M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1575.9% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | -1464.0% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -1575.9% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| ROA | -13.0% | -9.9% | · | -11.1% | -11.6% | -10.1% | · | -12.3% | -9.7% | -12.7% | · | -8.3% | -9.0% | -6.8% | · | -4.7% | |
| ROE | -14.2% | -10.5% | · | -12.4% | -12.7% | -11.0% | · | -14.1% | -10.7% | -14.5% | · | -9.1% | -9.8% | -7.3% | · | -5.0% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.0 | 15.7 | · | 13.7 | 12.8 | 18.0 | · | 9.8 | 16.3 | 10.5 | · | 11.5 | 17.1 | 14.8 | · | 26.6 | |
| Quick Ratio | 10.7 | 15.2 | · | 13.4 | 12.5 | 17.7 | · | 9.4 | 15.9 | 10.0 | · | 10.9 | 16.3 | 13.5 | · | 26.0 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.73 | $3.29 | · | $3.43 | $3.74 | $4.11 | · | $3.96 | $8.10 | $5.11 | · | $6.77 | $7.54 | $8.38 | · | $12.35 | |
| Revenue / Share | $0.02 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-0.37 | · | · | · | $-0.36 | · | · | · | $-0.91 | · | · | · | $-1.14 | · | · | |
| Cash / Share | $0.29 | $0.27 | · | $0.33 | $0.82 | $2.37 | · | $2.51 | $7.88 | $4.57 | · | $2.97 | $3.00 | $1.86 | · | $4.22 | |
| EPS (TTM) | $-1.37 | $-1.36 | · | $-1.20 | $-1.39 | $-1.49 | · | $-2.82 | $-3.19 | $-3.74 | · | $-6.13 | $-5.94 | $-5.70 | · | $-3.31 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-70M | $-63M | · | $-53M | $-51M | $-45M | · | $-42M | $-41M | $-42M | · | $-69M | $-67M | $-64M | · | $-37M | |
| Market Cap | $226M | $287M | · | $168M | $117M | $164M | · | $38M | $24M | $46M | · | $19M | $27M | $35M | · | $33M | |
| P/E | -2.8 | -3.8 | · | -3.6 | -2.2 | -2.9 | · | -0.6 | -0.7 | -1.1 | · | -0.3 | -0.4 | -0.5 | · | -0.9 | |
| P/B | 1.4 | 1.6 | · | 1.3 | 0.8 | 1.0 | · | 0.5 | 0.3 | 0.8 | · | 0.2 | 0.3 | 0.4 | · | 0.2 | |
| P / Tangible Book | 1.4 | 1.6 | · | 1.3 | 0.8 | 1.0 | · | 0.5 | 0.3 | 0.8 | · | 0.2 | 0.3 | 0.4 | · | 0.3 | |
| P / Cash Flow | · | -13.4 | · | · | · | -11.2 | · | · | · | -4.4 | · | · | · | -2.7 | · | · | |
| Earnings Yield | -35.9% | -26.1% | · | -27.6% | -45.9% | -35.0% | · | -154.1% | -153.4% | -93.3% | · | -367.1% | -248.5% | -182.1% | · | -111.8% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Net Income | $-57M | $-45M | $-40M | $-66M | $-47M |
| Diluted EPS | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 14.6 | 15.7 | 11.2 | 15.0 | 21.7 |
| Quick Ratio | 14.2 | 15.5 | 10.7 | 14.7 | 21.2 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-56M | $-36M | $-38M | $-27M | $-35M |
Institutional owners (13F) 126 filers · $198.1M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
126
Value held
$198.1M
New positions
26
Exited positions
17
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 26 (-6 vs prior Q) | 17 (-4 vs prior Q) | 50 (+2 vs prior Q) | 29 (+5 vs prior Q) | -2.1M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | $27,154,562 | 5,207,011 | 13.71% | Shares |
| BlackRock, Inc. | $13,994,565 | 3,663,499 | 7.06% | Shares |
| VANGUARD GROUP INC | $12,748,844 | 2,391,903 | 6.44% | Shares |
| MILLENNIUM MANAGEMENT LLC | $11,846,454 | 3,101,166 | 5.98% | Shares |
| Velan Capital Investment Management LP | $10,866,571 | 2,844,652 | 5.49% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $8,786,508 | 2,300,133 | 4.44% | Shares |
| Blackstone Inc. | $8,654,263 | 2,265,514 | 4.37% | Shares |
| ORBIMED ADVISORS LLC | $8,480,400 | 2,220,000 | 4.28% | Shares |
| Sio Capital Management, LLC | $7,341,551 | 1,921,872 | 3.71% | Shares |
| ACORN CAPITAL ADVISORS, LLC | $6,693,079 | 1,752,115 | 3.38% | Shares |
| Integral Health Asset Management, LLC | $5,730,000 | 1,500,000 | 2.89% | Shares |
| 5AM Venture Management, LLC | $5,232,567 | 1,369,782 | 2.64% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $5,067,467 | 1,326,246 | 2.56% | Shares |
| CITADEL ADVISORS LLC | $4,707,635 | 1,232,365 | 2.38% | Shares |
| STATE STREET CORP | $4,080,887 | 1,068,295 | 2.06% | Shares |
| Qube Research & Technologies Ltd | $3,993,871 | 1,045,516 | 2.02% | Shares |
| Balyasny Asset Management L.P. | $3,921,960 | 1,026,691 | 1.98% | Shares |
| BAKER BROS. ADVISORS LP | $3,711,565 | 971,614 | 1.87% | Shares |
| ADAR1 Capital Management, LLC | $3,592,756 | 940,512 | 1.81% | Shares |
| BANK OF AMERICA CORP /DE/ | $3,369,924 | 882,179 | 1.70% | Shares |
| MARSHALL WACE, LLP | $2,677,900 | 701,021 | 1.35% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $2,611,855 | 683,230 | 1.32% | Shares |
| NORTHERN TRUST CORP | $2,109,809 | 552,306 | 1.06% | Shares |
| Point72 Asset Management, L.P. | $2,096,920 | 548,932 | 1.06% | Shares |
| GOLDMAN SACHS GROUP INC | $2,086,587 | 546,227 | 1.05% | Shares |
| Catalio Capital Management, LP | $1,986,965 | 520,148 | 1.00% | Shares |
| MORGAN STANLEY | $1,942,218 | 508,434 | 0.98% | Shares |
| Walleye Capital LLC | $1,930,750 | 505,432 | 0.97% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1,878,130 | 491,657 | 0.95% | Shares |
| UBS Group AG | $1,744,873 | 456,773 | 0.88% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $1,278,489 | 334,683 | 0.65% | Shares |
| Verdad Advisers, LP | $1,192,791 | 312,249 | 0.60% | Shares |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $1,129,058 | 295,565 | 0.57% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $960,730 | 251,500 | 0.48% | Shares |
| OPPENHEIMER & CO INC | $910,543 | 238,362 | 0.46% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $798,262 | 208,969 | 0.40% | Shares |
| Jump Financial, LLC | $775,842 | 203,100 | 0.39% | Shares |
| CIBC WORLD MARKET INC. | $636,011 | 166,495 | 0.32% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $603,449 | 157,971 | 0.30% | Shares |
| Bank of New York Mellon Corp | $525,971 | 137,689 | 0.27% | Shares |
| J. Goldman & Co LP | $515,700 | 135,000 | 0.26% | Shares |
| SUPERSTRING CAPITAL MANAGEMENT LP | $463,966 | 121,457 | 0.23% | Shares |
| Fisher Asset Management, LLC | $380,342 | 99,566 | 0.19% | Shares |
| AMERICAN CENTURY COMPANIES INC | $376,220 | 98,487 | 0.19% | Shares |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $325,961 | 85,330 | 0.16% | Shares |
| Nuveen, LLC | $277,371 | 72,610 | 0.14% | Shares |
| TWO SIGMA INVESTMENTS, LP | $266,071 | 69,652 | 0.13% | Shares |
| FMR LLC | $260,524 | 68,200 | 0.13% | Shares |
| XTX Topco Ltd | $244,281 | 63,948 | 0.12% | Shares |
| RHUMBLINE ADVISERS | $241,589 | 63,245 | 0.12% | Shares |
Activists & 5%+ owners 8 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Deerfield Partners, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., James E. Flynn | Jan. 8, 2021 | · | Initial filing | · | SEC |
| Opaleye Management Inc., Opaleye, L.P., James Silverman ×3 filings | Sept. 25, 2020 | · | Initial filing | · | SEC |
| Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., James E. Flynn ×6 filings | Jan. 17, 2020 | · | Initial filing | · | SEC |
| Abingworth LLP, Abingworth Bioventures VI, LP | Jan. 17, 2020 | · | Initial filing | M&A / sale | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP 98-040-3543 ×3 filings | Nov. 14, 2019 | · | Initial filing | Board campaign | SEC |
| TVM Life Science Ventures VI L.P., TVM Life Science Ventures VI GmbH & Co. KG, TVM Life Science Ventures Management VI L.P., Hubert Birner, Stefan Fischer, Helmut Schuehsler ×2 filings | Aug. 2, 2017 | · | Initial filing | Passive investment | SEC |
| Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Mgmt III, L.P., Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., James E. Flynn | June 29, 2017 | · | Initial filing | Passive investment | SEC |
| Skyline Venture Partners Qualified Purchaser Fund IV, L.P., Skyline Venture Management IV, LLC, John G. Freund, Yasunori Kaneko | Nov. 3, 2014 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 41 insiders · 16 officers · 20 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Jesse Shefferman | CEO and President | June 29, 2026 M | 691,832 | 0 | 1 | $-882,160 |
| Timothy P Noyes | President and CEO | Jan. 31, 2019 A | 0 | 0 | 0 | $0 |
| Patrick Fabbio | Chief Financial Officer | Jan. 26, 2026 F | 64,115 | 0 | 0 | $0 |
| Blaine Davis | Chief Financial Officer | July 15, 2022 F | 20,662 | 0 | 0 | $0 |
| George Arthur Eldridge, | Sr VP, CFO, Treasr, Asst Secy | Jan. 18, 2019 A | 29,132 | 0 | 0 | $0 |
| William Conkling | Chief Commercial Officer | June 2, 2026 F | 69,992 | 0 | 0 | $0 |
| Jacqueline Zummo | Chief R&D Officer | April 8, 2026 S | 94,827 | 0 | 2 | $-124,989 |
| Hannah Fry | VP, Controller | Jan. 26, 2026 F | 42,723 | 0 | 0 | $0 |
| Leonardo Viana Nicacio | Chief Medical Officer | Jan. 16, 2026 A | 78,181 | 0 | 0 | $0 |
| Jathin Bandari | Chief Medical Officer | Jan. 19, 2024 A | 56,704 | 0 | 0 | $0 |
| Julio Casoy | Chief Medical Officer | Jan. 9, 2020 A | 45,500 | 0 | 0 | $0 |
| Steven Keith Burke | SVP and Chief Medical Officer | March 15, 2019 G | 26,332 | 0 | 0 | $0 |
| Bradley J Hartman | VP, People | Jan. 18, 2019 A | · | 0 | 0 | $0 |
| Matthew Paul Kowalsky | VP, Legal and Secretary | Jan. 18, 2019 A | 29,479 | 0 | 0 | $0 |
| Scott E. Toner | Senior VP of Commercial | Jan. 18, 2019 A | 23,357 | 0 | 0 | $0 |
| Gottlieb Daniel Philip | VP Corporate Development | Jan. 18, 2019 A | 244 | 0 | 0 | $0 |
| Michael Edward Solomon | Director | June 15, 2026 A | 26,500 | 0 | 0 | $0 |
| Jane Huang | Director | June 15, 2026 A | · | 0 | 0 | $0 |
| Barry P Flannelly | Director | June 15, 2026 A | · | 0 | 0 | $0 |
| Cynthia Smith | Director | June 15, 2026 A | · | 0 | 0 | $0 |
| Richard S Levy | Director | June 15, 2026 A | 51,000 | 0 | 0 | $0 |
| Roger Garceau | Director | June 15, 2026 A | 33,000 | 0 | 0 | $0 |
| Gregory Sargen | Director | June 15, 2026 A | 31,000 | 0 | 0 | $0 |
| Luke M Beshar | Director | June 15, 2026 A | 198,000 | 0 | 0 | $0 |
| Scott Braunstein | Director | June 9, 2020 A | 26,500 | 0 | 0 | $0 |
| John Gordon Freund | Director | Nov. 8, 2019 C | 2,175,882 | 0 | 0 | $0 |
| Hubert Birner | Director | June 8, 2018 A | 1,943,059 | 0 | 0 | $0 |
| Paul J Hastings | Director | June 8, 2018 A | · | 0 | 0 | $0 |
| Scott A Canute | Director | June 8, 2018 A | · | 0 | 0 | $0 |
| Garen G Bohlin | Director | June 8, 2018 A | 53,312 | 0 | 0 | $0 |
| Jonathan S Leff | Director | June 8, 2018 A | · | 0 | 0 | $0 |
| Brendan O'Leary | Director | June 9, 2016 A | 1,387,198 | 0 | 0 | $0 |
| Dmitry Kobyzev | Director | June 2, 2015 A | 1,165,344 | 0 | 0 | $0 |
| Gregory D Phelps | Director | June 2, 2015 A | · | 0 | 0 | $0 |
| Opaleye Management Inc. | 10% owner | Sept. 12, 2024 S | 45,000 | 0 | 0 | $0 |
| Opaleye, L.P. | 10% owner | Jan. 9, 2020 A | 2,208,472 | 0 | 0 | $0 |
| Martin Sebastian Olivo | · | June 10, 2021 P | 14,344 | 0 | 0 | $0 |
| Randall Marshall | · | Sept. 14, 2020 S | 585,600 | 0 | 0 | $0 |
| Timothy Haines | · | Nov. 12, 2019 C | 2,144,517 | 0 | 0 | $0 |
| Abingworth LLP | · | Nov. 12, 2019 C | 2,144,517 | 0 | 0 | $0 |
| Stuart A Kingsley | · | June 8, 2018 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 17 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IWC · iShares Trust | 0.05% | 179,945 SH | Sept. 11, 2026 | Daily |
| VFMO · VANGUARD WELLINGTON FUND | 0.03% | 141,979 SH | Aug. 19, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 300,912 SH | Aug. 19, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 45,581 SH | Aug. 19, 2026 | Daily |
| RSSL · Global X Funds | 0.01% | 24,988 NS | July 31, 2026 | N-PORT |
| IWM · iShares Trust | 0.01% | 1,339,324 SH | Sept. 11, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.00% | 125,321 NS | July 31, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.00% | 3,715 NS | July 31, 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.00% | 6,250 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 5,791 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 18,477 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 20,174 NS | July 31, 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 7,914 NS | July 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 586,965 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,657,879 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3,185 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 472,468 SH | Sept. 11, 2026 | Daily |
TARA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 14 analysts
BUY
Median target
$26.00
+863.0%
3 21.4%
Strong Buy
10 71.4%
Buy
1 7.1%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
7 analysts · 2026-10-01Mean target $25.71 +852.4%
← Below all targets
Current price $2.70
Low$20.00
Mean$25.71
High$30.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| TARA | $286M | -4.0 | · | · | -33.7% | · |
| DTIL | $100M | -1.2 | -50.1% | -133.4% | -72.4% | · |
| ORGO | $658M | 34.5 | 17.0% | 6.6% | 13.9% | · |
| AVXL | · | -16.5 | -36.1% | -991.4% | · | · |
| ALXO | $61M | -0.6 | · | · | -225.0% | · |
| VYGR | $232M | -1.9 | -49.5% | -296.5% | -54.4% | · |
| PEPG | $448M | -3.1 | · | · | -82.0% | · |
| NERV | $174M | -0.1 | · | · | 339.5% | · |
| NBP | $1.06B | -19.0 | · | · | -21.4% | · |
| CMPX | $958M | · | · | · | -45.9% | · |
| TNXP | $200M | -1.1 | 29.8% | -946.2% | -60.0% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 11, 2026